NEW YORK/WHITEHOUSE STATION, New Jersey (Reuters) - Merck & Co. (NYSE:MRK - news), facing falling sales and thousands of Vioxx lawsuits, on Thursday unveiled two new cholesterol drugs and an austerity program that will increase cost savings by another $1 billion through 2010, sending shares higher. The company provided the details at its annual meeting with industry analysts and portfolio managers at Merck headquarters in Whitehouse Station, New Jersey. Its shares rose 2 percent while those of some rivals in the cholesterol market fell.
